Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07644312 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Collaborators expanded, about 5 wordsv2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to further evaluate feasibility and tolerability of Opdualag for patients with replication repair deficient HGG, including DIPG.
Trial Details
NCT Number NCT07644312
Lead Sponsor Nationwide Children's Hospital
Collaborators: The Hospital for Sick Children
Conditions
(from sponsor)		 High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Replication Repair Deficient
Related terms Diffuse Intrinsic Pontine Glioma, Glioma
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov